MannKind Corporation (NASDAQ:MNKD)
Industry: Healthcare

Listed 3 Consecutive Market Days. On List as of 01/23/2012 Through 01/26/2012

MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes patients in the United States. Its approved product is AFREZZA, a rapid-acting, inhaled insulin used to control high blood sugar in adults with type 1 and type 2 diabetes. MannKind Corporation has license and collaboration agreement with Sanofi-Aventis Deutschland GmbH for the development of AFREZZA. The company was founded in 1991 and is headquartered in Valencia, California.

Current Quote*
Last: $0.789
Change: -0.051
Book: $198.300
Volume: 6,118,425

As Of: 08/26 19:25 ET
*Quotes delayed by 20min.

Graphs for MNKD


3 Month Graph


6 Month Graph


1 Year Graph